Why Weight Loss Stops on Mounjaro — and What Actually Helps

The biggest misconception: a plateau means Mounjaro has stopped working

The most common thing people believe when their weight loss stops on Mounjaro is that the medicine has simply given up. It rarely has. What's actually happening is that your body has become more metabolically efficient at a lower weight. Your basal metabolic rate falls as you lose mass, your appetite hormones partially compensate, and the energy deficit that drove early losses narrows (sometimes to zero) even if your eating habits haven't changed at all. This is not a Mounjaro problem; it is a basic feature of human physiology, and it affects people on every form of weight-loss treatment.

Clinical trial data support this: in the SURMOUNT-1 study, which followed thousands of adults over 72 weeks, the sharpest losses came in the first few months and then the curve flattened, yet participants continued to lose weight overall through sustained treatment. A stall mid-treatment is a normal point on that curve, not the end of it. If you want to understand the broader mechanics, the reasons weight loss pauses on Mounjaro are worth reading through carefully.

There is a separate, less-discussed possibility: that your dose is no longer at the level that fully suppresses appetite. Tirzepatide is titrated from 2.5 mg upward for a reason, different people respond differently at each step. If you are still on an earlier dose and you've stopped losing weight on Mounjaro, a prescriber-led review is the appropriate next step, not self-adjustment.

What genuinely causes weight loss to stop, and what patients often miss

Several concrete factors show up repeatedly when weight loss stops on tirzepatide treatment. The first is calorie creep: appetite suppression is strong early in treatment, but it often softens slightly over time, and portion sizes drift up in ways that are easy to miss. One practical check you can do right now (it takes under a minute to set up) is to photograph every meal for a week without changing anything. Reviewing those photos with a prescriber or dietitian tends to be illuminating.

The second is liquid calories. Juice, flavoured coffees, full-fat milky drinks and alcohol are often underestimated because they don't register as food. The third is reduced physical activity: as you feel better at a lower weight, you may paradoxically move less formally, because incidental movement has also changed. The fourth is stress and poor sleep, both of which elevate cortisol and blunt weight loss independently of food intake.

Sometimes the answer is simpler: not enough time has passed. Mounjaro works over weeks to months, not days, and a three-week plateau at a stable dose is not necessarily a signal that anything is wrong. The guide to what a true plateau looks like on tirzepatide can help you judge whether what you're experiencing is typical or warrants a clinical conversation.

When to speak to your prescriber, and what they can actually do

Not every plateau needs action beyond patience, but some do. Bring it up with your prescriber if your weight has not changed over four to six weeks and you are confident your eating and activity have stayed consistent. They may review whether you are at an appropriate dose for your stage of treatment, whether any other medicines or health conditions could be interfering, and whether your lifestyle context has shifted in ways that change the picture.

Dose titration is the most direct clinical lever, moving to the next licensed strength is a structured, supervised process guided by your tolerance and your response so far. It is not a shortcut; it is part of the design of tirzepatide treatment. For context on how the full titration pathway works, the tirzepatide overview covers the licensed schedule and what each phase is intended to do.

If you are considering stopping treatment because of a plateau, it is worth reading about what happens when you stop Mounjaro before making that decision, the consequences of discontinuation are a clinical consideration in their own right. In January 2026, the MHRA published an updated Drug Safety Update for GLP-1 medicines reinforcing that these medicines should be used under clinical supervision throughout; that guidance is accessible via the MHRA's Yellow Card portal.

What nume's prescribers look at when weight loss stalls

At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is approved, this isn't a formality. If weight loss has stopped, that review is the moment to say so. Our prescribers look at your recorded progress, your current dose, your reported side effects, and whether the titration schedule makes clinical sense for where you are. That conversation doesn't require booking a separate appointment.

For people further into treatment who want to understand the wider landscape of options, our weight loss overview sets out the treatments we work with and how they compare clinically. And if cost has become a factor in whether to continue, our Mounjaro cost page explains exactly what is included in our pricing, there are no hidden fees and no subscription. The NHS's own patient guidance on tirzepatide, available at nhs.uk/medicines/tirzepatide, also covers what to expect when treatment is going well and what warrants a call to your care team.

If you're ready to review your treatment with a prescriber, check your eligibility to start that conversation today.